LGVN Share Price Performance
US$0.74
-0.02 (-2.64%)
89.7% undervalued intrinsic discount
US$7.15
Fair Value
Price US$0.74
AnalystConsensusTarget US$7.15
AnalystLowTarget US$3.00
AnalystHighTarget US$10.45
Fair ValueUS$7.15
Share Pricen/a
Longeveron Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
LGVN Community Narratives
AN
Fair Value
·Fair Value US$7.15 89.7% undervalued intrinsic discount
FDA Alignment And HLHS Trial Will Enable Market Access
1users have liked this narrative
1users have commented on this narrative
7users have followed this narrative
AN
Fair Value
·Fair Value US$3 75.3% undervalued intrinsic discount
High Costs And HLHS Hurdles Will Crimp Prospects, Spark Renewal
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$10.45 92.9% undervalued intrinsic discount
HLHS Trials And Aging Demographics Will Expand Regenerative Markets
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
High Costs And HLHS Hurdles Will Crimp Prospects, Spark Renewal
Longeveron is chasing big medical needs with an experimental cell therapy, but its path depends on clear trial wins and regulators saying yes. The catch is that costs keep climbing while cash looks tight, so the company may need more funding before it can prove it can sell a real product.Read more
AN
US$3
75.3% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
207.27x
Price in 2029
US$2.05
FDA Alignment And HLHS Trial Will Enable Market Access
A small biotech bets on a cell therapy for a rare and deadly heart condition in infants, with a key trial result and a clearer path with regulators that could open the door to its first real product launch. The upside comes with a catch: ongoing losses and a short cash runway mean it may need more funding before it can reach the market.Read more
AN
US$7.15
89.7% undervalued intrinsic discount
Fair Value
Profit Margin
34.63%
Future PE
11.42x
Price in 2029
US$4.89
HLHS Trials And Aging Demographics Will Expand Regenerative Markets
Key Takeaways Strong clinical and regulatory positioning in multiple rare diseases, combined with advantageous designations, bolsters expedited approvals, commercial potential, and recurring revenue streams. Leadership in next-generation regenerative therapies and scalable manufacturing supports long-term growth, pipeline expansion, and improving profitability amid increasing healthcare demand.Read more
AN
US$10.45
92.9% undervalued intrinsic discount
Fair Value
Profit Margin
14.17%
Future PE
63.94x
Price in 2028
US$17.22
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
LGVN: Trial Safety Progress And EMA SME Status Will Support Future Repricing
Fair Value: US$3 75.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LGVN: Upcoming HLHS Trial Outcome Will Drive Upside Potential
Fair Value: US$7.15 89.7% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
HLHS Trials And Aging Demographics Will Expand Regenerative Markets
Fair Value: US$10.45 92.9% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Longeveron Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.74
- 69.76%
- -1,977.59%
- 0%
About LGVN
- Founded
- 2014
- Employees
- 38
- CEO
- WebsiteView website
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
